Tacrolimus Prevents TWEAK-Induced PLA2R Expression in Cultured Human Podocytes

Tacrolimus Prevents TWEAK-Induced PLA2R Expression in Cultured Human Podocytes

Primary membranous nephropathy is usually caused by antibodies against the podocyte antigen membrane M-type phospholipase A2 receptor (PLA2R). The treatment of membranous nephropathy is not fully satisfactory. The calcineurin inhibitor tacrolimus is used to treat membranous nephropathy, but recurren...

Full description

Bibliographic Details
Main Authors: Leticia Cuarental, Lara Valiño-Rivas, Luis Mendonça, Moin Saleem, Sergio Mezzano, Ana Belen Sanz, Alberto Ortiz, Maria Dolores Sanchez-Niño
Format: Article
Language:English
Published: MDPI AG 2020-07-01
Series:Journal of Clinical Medicine
Subjects:
podocyte
nephrotic syndrome
membranous nephropathy
Fn14
TWEAK
tacrolimus
Online Access:https://www.mdpi.com/2077-0383/9/7/2178

Internet

https://www.mdpi.com/2077-0383/9/7/2178

Similar Items